Evidence map›Paper›PMID 42060936›Full record

ReviewInternal medicine journal2026

Haemochromatosis - a modern clinician's guide.

James G Fiori, John K Olynyk

Abstract readReview
In one paragraph

Review in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

James G FioriDepartment of Gastroenterology and Hepatology, Fiona Stanley Hospital, Perth, Western Australia, Australia.ORCID https://orcid.org/0000-0002-0630-6102
John K OlynykDepartment of Gastroenterology and Hepatology, Fiona Stanley Hospital, Perth, Western Australia, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haemochromatosis is an inherited disorder of iron metabolism affecting approximately 100 000 Australians. Iron overload may result in end organ dysfunction, most commonly manifesting as chronic liver disease, arthropathy and endocrinopathies. End organ complications can be prevented, minimised or reversed, with early diagnosis and initiation of treatment in the form of venesection. Our understanding of the pathogenesis and epidemiological characteristics of the disorder has evolved in recent decades, including identification of HFE gene variants and sex-specific differences in phenotypic expression of the disorder. This clinical perspective article summarises the up-to-date evidence regarding the pathophysiology, clinical manifestations and treatment recommendations for haemochromatosis.

Indexed as

HemochromatosisPractice Guidelines as TopicAustraliaHemochromatosis ProteinHumansIronHemochromatosis ProteinHFE protein, humanIronHFE haemochromatosisiron overload

Identifiers

PMID42060936
PMCPMC13193489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.